Technology Vision Group LLC is excited to announce the
launch of a new and unique additional component to biopartnering.com
-- video profiles. This exciting new feature will give Open House and
Emerging Company presenters at BioPartnering Europe (BPE) the ability
to add a short video to their biopartnering.com profile and thus
promote their company in a dynamic and engaging manner.
This additional video capability within biopartnering.com
demonstrates BPE's commitment to finding new ways to showcase
companies, and reaffirms biopartnering.com's position as the leading
life science conference collaboration tool, enabling BioPartnering
Europe presenters to achieve maximum effectiveness from their
conference experience. For a video profile demonstration please see
http://www.techvision.com/bpe/announcements/detail.php?id=46
"At Warwick Effect Polymers, we were delighted with the
possibility to use video as an additional communication medium,"
stated Noru Tsalic, Chief Executive Officer. "It nicely complements
the other web-based capabilities of biopartnering.com and enhances our
message to potential and existing partners. It is often said that one
picture is worth a thousand words. In this case, one video is probably
worth a thousand pictures!"
Topical Debate from Industry Leaders
One of the most popular and successful aspects of BPE is the
BioPartnering Leadership Sessions series, in which leading figures
from the financial, pharmaceutical, and biotechnology industries
address cutting-edge themes of interest to corporate decision-makers.
Each year, topics are chosen that reflect the most pressing issues
affecting the life science industries, and all speakers bring their
wealth of experience to the BioPartnering Europe audience. This series
offers delegates the opportunity to better understand issues of
relevance to doing business in Europe, and in some cases, in other
parts of the world.
This year, one of the Leadership sessions is entitled "Future of
Biotechnology Deal-Making." Top executives from two of the world's
largest life science companies, AstraZeneca and Merck & Co. will
discuss the future of biotechnology deal-making, and the role played
by big pharma, the sources of product innovation, how large and small
companies can work together, and the types of deals that make sense in
2006.
This Leadership Session will be chaired and moderated by Mike
Ward, the European editor for BioCentury Publications, and will
feature insights from Dr. John Patterson, Executive Director of
Development for AstraZeneca, as well as Dr. Merv Turner, Senior Vice
President of World Licensing and External Research for Merck & Co.
View the conference program online at:
http://www.techvision.com/bpe/program/
Full details about BioPartnering Europe online at:
http://www.techvision.com.
-0-
*T
Conference Sponsors and Supporters
Producer:
Technology Vision Group LLC
Premium Sponsors:
AstraZeneca, Taylor Wessing
Gold Sponsors:
Cooley Godward LLP, Deloitte, Ferghana Partners Group, Wyeth
Silver Sponsors:
Amgen, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson &
Johnson, Merck & Co., Inc., Novartis, Pfizer, Roche, TAP
Pharmaceutical Products Inc., Welsh Development Agency - Bioscience
Unit
Conference Sponsors:
BioQuebec, Farris, Vaughan, Wills, & Murphy LLP, Genzyme, Life Science
Analytics, NovaQuest
Conference Supporters:
BayBio, BioCentury, Business Wire, Citigate, European
Biopharmaceutical Review, Global Bioscience Partnership, Nature
Biotechnology, Red Herring, U.S. Commercial Service
Official Carrier:
British Airways
Emerging Company Presenters:
Alchemia Limited, Amorfix Life Sciences Ltd., Antibe Therapeutics
Inc., Athenagen, Avexa Limited, BioXell SpA, Borean Pharma A/S, BT
Pharma, Celldex Therapeutics, Clera, Inc., EcoBiotics Ltd., GammaCan
Int. Inc., Haptogen Ltd., hemoCORM, Karus Therapeutics, Lymphosign
Inc., Mimetogen Pharmaceuticals, MNLpharma Ltd., ODC Therapy,
Pharmacopeia, PolyMedix Inc., ProtAffin Biotechnologie AG, Psynova
Ltd., Rincon Pharmaceuticals, Inc., SantoSolve, Senexis Ltd., Synosis
Therapeutics, Syntaxin, Y's Therapeutics, Zyentia Limited
Open House Presenters:
Ablynx, ACE BioSciences A/S, Acrux Ltd., Aegera Therapeutics Inc.,
AerovectRx Corporation, AlgoNomics NV, Alligator Bioscience, amaxa
GmbH, Ambit Biosciences, AmpliMed Corporation, Antisoma, Array
BioPharma Inc., Arrow Therapeutics Ltd., Asperva Pharmaceuticals,
Astex Therapeutics Ltd., Avecia Limited, Avera Pharmaceuticals, Inc.,
Avid Bioservices, Avidex Limited, Banner Pharmacaps, BioFocus, Biolex
Therapeutics, Boston Life Sciences, Inc., Callisto Pharmaceuticals,
Cell Genesys, Inc., CombinatoRx, Covx, Curis Pharmaceuticals, Cylene
Pharmaceuticals Inc., Cytokinetics, Inc., Dako North America, Digilab
BioVisioN GmbH, Dimera Inc., DIREVO Biotech AG, Dyax Corp., Emergent
Biosolutions, Evolutec, Evotec (UK) Ltd., ExonHit Therapeutics, Faust
Pharmaceuticals, Favrille, Inc., Fermavir Pharmaceuticals Inc., Gala
Biotech, a business unit of Cardinal Health, GangaGen Inc., Health
Protection Agency, Icagen, Inc., ImmuPharma PLC, INC DataSpectrum,
Indevus Pharmaceuticals, Inc., Ingenium Pharmaceuticals AG, Inimex
Pharmaceuticals, Inc., InNexus Biotechnology Inc., Intendis GmbH,
Intermune, Inc., Istituto Superiore di Sanita, Jiangsu Simcere
Pharmaceutical R&D Co., Ltd., Jurilab Ltd., Liponex Inc., Locus
Pharmaceuticals Inc., MaxCyte, Inc., Medicago Inc., MedPharm Ltd,
Miltenyi Bioprocess, MolMed SpA, Monash Commercial Pty Ltd, MorphoSys
AG, Nerites Corporation, Neuren Pharmaceuticals Inc., Novozymes A/S,
OctoPlus, OMRIX Pharmaceuticals, Inc., Orient EuroPharma Ltd., Oxxon
Therapeutics Ltd., Paradigm Therapeutics Ltd., Perceptronix Medical
Inc., Phylogica Ltd., PIramed Ltd., PLx Pharma, Portola
Pharmaceuticals, PTC Therapeutics, Inc., RNTech, Sapphire
Therapeutics, Scottish Biomedical, SGX Pharmaceuticals, Inc., SR
Pharma / Atugen AG, Stem Cell Therapeutics, Threshold Pharmaceuticals,
TiGenix NV, TopoTarget UK Ltd., Transgene S.A., Trigen Holdings AG,
Tripos Discovery Research Ltd., UCB Celltech, Urigen, Warwick Effect
Polymers Ltd., Welichem Biotech Inc., WuXi PharmaTech Co. Ltd., Xenome
Ltd, XOMA Ltd., ZIOPHARM Oncology, Inc
*T
